Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542

Nicholas J. Laping(GlaxoSmithKline (United Kingdom)), Eugene T. Grygielko(GlaxoSmithKline (United Kingdom)), Anil Mathur(GlaxoSmithKline (United States)), Sebastian Butter(GlaxoSmithKline (United States)), Jennifer M. Bomberger(GlaxoSmithKline (United Kingdom)), Christopher Tweed(GlaxoSmithKline (United States)), W. Martin(GlaxoSmithKline (United Kingdom)), James A. Fornwald(GlaxoSmithKline (United States)), Ruth Lehr(GlaxoSmithKline (United Kingdom)), John D. Harling(GlaxoSmithKline (United States)), Laramie M. Gaster(GlaxoSmithKline (United States)), James F. Callahan(GlaxoSmithKline (United Kingdom)), Barbara A. Olson(GlaxoSmithKline (United Kingdom))
Molecular Pharmacology
July 1, 2002
Cited by 650

Abstract


Related Papers

No related papers found

Powered by citation graph analysis